Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal, rebranding as migraine biotech with $245M financing

Fulcrum Therapeutics agreed on August 16, 2026, to merge with privately held Slate Medicines in an all-stock transaction, a move that pivots the Nasdaq-listed company away from its rare hematology pipeline following the recent discontinuation of its lead drug candidate. The combined company will operate under the name Slate Medicines and is expected to trade on Nasdaq under the ticker symbol SLTE upon closing, which is targeted for the fourth quarter of 2026, pending stockholder approval and customary conditions. The deal is supported by a concurrent, oversubscribed private placement raising $245 million from a syndicate of healthcare investors, with proceeds expected to fund operations into 2029.

Slate's lead asset, SLTE-1009, is a clinical-stage subcutaneous anti-PACAP/VIP monoclonal antibody being developed for the preventative treatment of migraine. Slate CEO Gregory Oakes is expected to lead the combined company. FULC shares rallied on the announcement, with options volume in the stock reaching 11,758 contracts on Monday, reflecting elevated investor interest.

Law firm Kaplan Fox also announced a separate investigation into potential federal securities law violations by Fulcrum in connection with the transaction.